J Korean Ophthalmol Soc > Volume 53(10); 2012 > Article
Journal of the Korean Ophthalmological Society 2012;53(10):1458-1464.
DOI: https://doi.org/10.3341/jkos.2012.53.10.1458    Published online October 15, 2012.
Combined Therapy of Bevacizumab and Grid Photocoagulation for Macular Edema in Branch Retinal Vein Occlusion.
Seung Min Lee, Ik Soo Byon, Ji Eun Lee, Boo Sub Oum
Department of Ophthalmology, Pusan National University School of Medicine, Busan, Korea. jlee@pusan.ac.kr
망막분지정맥폐쇄에 합병된 황반부종에서 유리체강내 베바시주맙 주입과 격자광응고술 병합요법
이승민⋅변익수⋅이지은⋅엄부섭
Department of Ophthalmology, Pusan National University School of Medicine, Busan, Korea
Abstract
PURPOSE
To evaluate clinical outcomes of a combined therapy of intravitreal bevacizumab and grid laser photocoagulation for macular edema in branch retinal vein occlusion (BRVO). METHODS: In the present retrospective study, medical records of patients who were treated with intravitreal bevacizumab injection for macular edema due to BRVO were reviewed. The eyes were divided into 2 groups, the combined therapy group of intravitreal bevacizumab and grid laser photocoagulation, and the monotherapy group of intravitreal bevacizumab. Visual acuity and central subfield macular thickness were investigated at 1, 2 and 6 months. Recurrence rate was compared between the 2 groups. RESULTS: Among 49 eyes, 18 eyes underwent macular grid photocoagulation and 31 eyes did not receive laser treatment. Laser photocoagulation was performed at 1.2 months after injection on average. Visual acuity improved significantly at 2 and 6 months in the combined therapy group, and at 1, 2 and 6 months in the monotherapy group. Macular thickness decreased significantly compared to baseline at all visits in both groups. There was no significant difference in visual acuity and foveal thickness between the 2 groups. Recurrence at 6 months was significantly less frequent in the combined therapy group (3 eyes, 17%) then in the monotherapy group (14 eyes, 45%, p = 0.046). CONCLUSIONS: Combined grid photocoagulation after intravitreal bevacizumab injection lowered the recurrence rate of macular edema complicated with BRVO.
Key Words: BRVO;Combination therapy;Intravitreal bevacizumab injection;Macular edema


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next